publication date: Sep 9, 2011
|
author/source: Integra Communications Limited
Synthetic
peptide manufacturer, Pepceuticals, has been given MHRA approval for the
manufacture of APIs following an additional £2 million investment in new
premises and state-of-the-art manufacturing facilities in Leicestershire, UK.
Pepceuticals is now the largest peptide cGMP manufacturer in mainland UK and is
the Research Council UK (RCUK) preferred supplier of peptides and
antibodies.
The 10,000
sq ft industrial unit has been equipped with eight large and medium sized,
high-tech cGMP laboratories, enabling Pepceuticals to offer a versatile service
to support research and in-process projects; from pre-clinical toxicology
studies through to early stage clinical trials and eventually to full
manufacturing capacity of approved APIs for larger clinical trials.
Managing
Director, Dr Kamal Badiani, who founded the company 13 years ago, said: "We are
absolutely delighted that our investment and hard work has culminated in this
vital approval. The peptide industry is booming and we have been
achieving 20% year on year growth for the past two years. We now have the
capacity and capability to deliver a complete chemistry manufacturing solution
to the pharmaceutical industry."
Since
gaining MHRA approval, Pepceuticals has already boosted staff numbers with the
appointment of a new Head of Sales, Daniel Milek who will be responsible for
opening up new trade opportunities with universities, pharmaceutical
manufacturers and research bodies. Daniel was previously employed as a Project
Leader at Thermo Fisher Scientific in Loughborough.
The
facilities at the Leicestershire base are continuing to be enhanced and have
recently included the installation of a Quatro Premier Xe Mass Spectrometer, a
Synapt G1 High Definition Mass Spectrometer, 2 Symphony® 12-channel peptide synthesisers
and an Overture
TM Robotic Peptide Library Synthesizer.
The company
is currently awaiting a further decision from the MHRA on its application for a
Specials Licence, allowing the firm to manufacture unlicensed products for use
in early studies and clinical trials. The license would be one of only a
handful issued in the UK.
For more information visit
www.pepceuticals.co.uk
Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!
Request your free copies HERE
Popular this Month
Top 10 most popular articles this month
Today's Picks
Looking for a Supplier?
Search by company or by product
Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.
Lab Bulletin is published by newleaf marketing communications ltd.